Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions
Nina Kok(AIMM Therapeutics (Netherlands)), Monica Raimo(University of Turin), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Zoë Dekkers, Anica Loos, Puck van den Broek, Inge Post, Thomas Bos(Leiden University), Bertine Niessen, Volker Huppert(Miltenyi Biotec (Germany))
Cited by 7
Related Papers
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
|PLoS ONE|2011|239
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
|Clinical Cancer Research|2017|211
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
|Frontiers in Immunology|2017|197